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Background: The main aim of the study was to evaluate if patients with oral squamous carcinomas in Northern
Norway differ from patients in other countries with regard to clinicopathological characteristics and also study the
influence of risk factors. Such a comparison is of demographical interest, and also important for the interpretation
of result from studies on prognostic biomarkers.
Methods: We describe clinicopathological characteristics of 133 North Norwegian patients diagnosed with
squamous cell carcinoma of the oral cavity in the period 1986–2002, and evaluate the significance of different risk
factors.
Results: The cohort consisted of 69 men and 64 women, giving male/female ratio of 1.1. Forty-seven of the 133
patients (35%) died of the disease within 5 years from diagnosis. There was no significant difference between the
genders concerning time to disease specific death, even though men both smoked and drank more alcohol than
women. As expected, the strongest predictors for disease specific death were tumour size and the presence of
regional lymph node metastasis. We also found that heavy smokers and drinkers presented with more advanced
disease, more often localized to the floor of mouth compared to non-smoking and abstinent patients, who more
often presented with tumours of the mobile tongue.
Conclusions: Our results correlate well with previously published clinicopathological data on comparable cohorts,
which is important when considering the applicability of results from biomarker studies performed on this material
compared to other cohorts, and vice versa.
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Squamous cell carcinoma (SCC) accounts for more than
90% of the malignant neoplasm’s in the oral cavity, which
includes tongue, floor of mouth, buccal mucosa, alveolar
rim and the hard and soft palate [1,2]. Globally, about
275,000 new cases of oral SCC (OSCC) are diagnosed
each year [3], but the incidence of OSCC show large
geographical variations. In the southern part of Asia and
in Latin America the incidence of OSCC is about 20
fold higher than in Northern Europe, and is actually the* Correspondence: sonja.steigen@unn.no
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unless otherwise stated.most common cancer among the male population in
some of the high-risk areas in Asia [3].
The lifetime risk of developing oral or oropharyngeal
cancer in Europe is estimated to be 1.85% for men and
0.37% for women [3]. Age-standardized incidence (rates
per 100 000) for lip and oral cancer in Northern Europe
is 5.1 for men and 2.5 for women [4]. In Norway the
equivalent numbers are 4.3 and 2.5. In these numbers
SCC of the lip accounts for approximately 40% of the
cases [5]. The incidence rates are higher in Western and
Eastern Europe than in northern or southern European
countries; France and Hungary presenting the highest
numbers, Greece and Cyprus the lowest [6,7]. In Northern
France, the oral cavity and oropharynx constitute the
second most common cancer sites in men, after lung [8].ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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explained by cultural differences which is influenced by
the exposure to risk factors [2]. The two best known risk
factors in the Western countries are tobacco and alcohol
abuse, which act strongly synergistically, and are estimated
to account for up to 75% of the disease burden in this part
of the world [7,9-11]. Koch et al. reported that cigarette
smoking increased the risk for OSCC 1.9 times in men
and 3 times in women. For persons who stop smoking,
the risk falls to non-smoker level in 10 years. Daily
drinkers (2 units/day) are reported to have an increased
oral cancer risk of 1.7, heavy drinkers up to 3. For persons
who smoke and drink alcohol daily, the odds ratio are
reported to be as high as 35 [12,13]. In Southern Asia
the chewing of betel quid and areca nuts explains the
high incidence [14,15]. The exposure to various risk
factors also has impact on the primary site of OSCC,
betel quid and areca nut chewing mainly disposing for
tumours arising in the buccal mucosa, while cigarette
smoking and alcohol are disposing for tumours in the
floor of mouth [1,12,16-18].
The most widely used classification-system for describ-
ing the anatomical extent of the disease is the Union for
International Cancer Controls TNM-system [19] which
grades primary tumour size and invasion features (T), re-
gional lymph node spread (N) and the presence of distant
metastasis (M). Survival time of the OSCC patients is
strongly associated with the TNM-stage, and the TNM-
classification system is still the most important guide for
treatment stratification in clinical practice [20,21]. By
morphological assessment, tumours are classified based
on the cancer cells differentiation into well, moderately
and poorly differentiated carcinomas [1]. Some report that
patients with well differentiated tumours live longer than
patients with low differentiated tumours [22,23], whereas
other report poor correlation between outcome and
tumour grade [24,25].
The acquired knowledge about the impact of human
papilloma virus (HPV) infection in oropharyngeal tumours
highlights the importance of distinguishing oropharyngeal
tumours from tumours in the oral cavity. An increasing
number of the tumours arising in the oropharynx are
thought to be HPV-driven. The behaviour and treatment
response of these tumours differ to such a degree from
HPV negative tumours that an increasing number of
scientists claim that they should be considered as two
different enteties [20,26]. In the oral cavity, though,
HPV-related tumours are uncommon, and the HPV-
status of the tumour has little impact on outcome
[27-29]. A tumour cell infected with an oncogenic
HPV-type, overexpress the tumour suppressor protein
p16INK4a due to retinoblastoma (Rb) gene inactivation
by the E7 oncoprotein [30]. In clinical practice the
HPV status of a tumour is often determined indirectlyby immunohistochemical identification of overexpres-
sion of the p16 protein [31,32].
In the present study we present a cohort of 133 OSCC
patients from Northern Norway. The population of
Northern Norway may be exposed to other risk factors
than people in other cohorts. The main aim of the study
was therefore to evaluate if patients with OSCC in
Northern Norway differ from patients in other countries
with regard to clinicopathological characteristics. Such a
comparison is not only of demographical interest, but is
also important for the interpretation of result from studies
on prognostic biomarkers performed on this cohort to
other populations, and for implementation of results




The cohort described in this paper consists of 133 patients
collected from the archives of the Department of Clinical
Pathology, University Hospital of North Norway. They
represent all patients diagnosed at the department with
primary SCC of the oral cavity (ICD-O, C02-C06) [33] in
the period 1986–2002. Second primaries were excluded.
The relevant clinical data and the tumours’ TNM-
classification [19] were retrieved from patients files,
including pathology reports and Statistics of Norway,
Cause of Death Registry. The N-stage was based on
clinical and radiological findings. The study was approved
by the Regional committees for Medical and Health Re-
search Ethics, Northern Norway (No. 22/2007).
Immunhistochemical staining of p16
Tissue microarray (TMA) blocks containing 2 cores of
0.6 mm from representative tumour tissue from all
patients were sectioned at 4 μm and transferred to
Superfrost + slides. The immunohistochemical staining
for p16 was done in the automated slide stainer Ventana
Benchmark, XT (Ventana Medical Systems, Inc., Roche,
Tucson Arizona, USA) at the Department of Clinical
Pathology, University Hospital of North Norway, using
the same protocols, and positive and negative controls as
in the clinical routine. The antibody used was a prediluted
mouse anti-p16, clone E6H4, Ventana, recognizing the
tumour suppressor p16INK4a protein. The slides were
pre-treated with cell conditioning 1 (CC1) at 95°C for
36 minutes, and the antibody incubation time was
28 minutes.
The staining was recorded as percentage of tumour
cells stained; (1 (<10%), 2 (10-50%), 3 (51-80%) and 4
(>80%), and was performed by one experienced path-
ologist (SES) and one head and neck surgeon (OR).
The scoring was easy to perform, as the majority of the
tissue samples were either completely negative, or clearly
Table 1 Clinicopathiological variables defined by gender and disease specific death (DSD)
Difference DSD
Men Women Gender All patients N
(n = 69) (n = 64) p-value* (n = 133) (% of total) DSD p*
Age
≤50 years 8 (12%) 9 (14%) p = 0.405 17 (13%) 4 (24%) 0.769
51-60 years 19 (28%) 11 (17%) 30 (23%) 12 (40%)
61-70 years 18 (26%) 14 (22%) 32 (24%) 14 (44%)
71-80 years 15 (22%) 15 (23%) 30 (23%) 9 (30%)
≥81 years 9 (13%) 15 (23%) 24 (18%) 8 (33%)
Tumor differentiation
Verrocous 1 (1%) 4 (6%) p = 0.474 5 (4%) 0 0.142
Well 28 (41%) 28 (44%) 56 (42%) 17 (30%)
Moderate 34 (49%) 27 (42%) 61 (46%) 25 (41%)
Poor 6 (9%) 5 (8%) 11 (8%) 5 (45%)
Tumor stage
T1 19 (28%) 24 (39%) p = 0.335 43 (32%) 8 (19%) <0.001
T2 25 (36%) 21 (33%) 46 (35%) 11 (24%)
T3 4 (6%) 7 (11%) 11 (8%) 7 (64%)
T4 18 (26%) 9 (14%) 27 (20%) 17 (63%)
Unknown 3 (4%) 3 (5%) 6 (5%) 4 (67%)
Lymph node status
N0 42 (61%) 40 (63%) p = 0.200 82 (62%) 21 (26%) <0.001
N +a 21 (30%) 13 (20%) 34 (26%) 21 (62%)
Unknown 6 (9%) 11 (17%) 17 (13%) 5 (29%)
SODb
Stage I 15 (22%) 17 (27%) p = 0.316 32 (24%) 4 (13%) <0.001
Stage II 19 (28%) 16 (25%) 35 (26%) 7 (20%)
Stage III 9 (13%) 11 (17%) 20 (15%) 10 (50%)
Stage IV 20 (29%) 10 (16%) 30 (23%) 21 (70%
Unknown 6 (9%) 10 (16%) 16 (12%) 5 (31%)
Primary site
Mobile tounge 34 (49%) 27 (42%) p = 0.038 61 (46%) 18 (30%) 0.548
Floor of mouth 21 (30%) 9 (14%) 30 (22%) 12 (40%)
Alveolar rim 9 (13%) 15 (23%) 24 (18%) 8 (33%)
Buccal mucosac 4 (6%) 7 (11%) 18 (14%) 9 (50%)
Palatec 1 (1%) 3 (5%)
Otherc 0 3 (5%)
Smoking
Never 8 (12%) 27 (42%) p < 0.001 35 (26%) 9 (26%) 0.566
Previous smoker 14 (20%) 6 (9%) 20 (15%) 7 (47%)
Smoker 41 (59%) 18 (28%) 59 (44%) 24 (41%)
Unknown 6 (9%) 13 (20%) 19 (14%) 7 (37%)
Alcohol consumption
Never 5 (7%) 23 (36%) p < 0.001 28 (21%) 6 (21%) 0.002
< once a week 27 (39%) 20 (31%) 47 (35%) 16 (34%)
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Table 1 Clinicopathiological variables defined by gender and disease specific death (DSD) (Continued)
> once a week 9 (13%) 1 (2%) 10 (8%) 2 (20%)
Daily 8 (12%) 3 (5%) 11 (8%) 7 (64%)
Unknown 20 (29%) 17 (27%) 37 (28%) 16 (43%)
IRFd
Non-smoker/non-drinker 10 (14%) 30 (47%) p < 0.001 40 (30%) 10 (25%) 0.120
Smoker/light drinkere 22 (32%) 13 (20%) 35 (26%) 12 (34%)
Smoker/heavy drinkere 17 (25%) 4 (6%) 21 (16%) 9 (43%)
Unknown 20 (29%) 17 (27%) 37 (28%) 16 (43%)
P16-stausf
Positiv 6 (10%) 4 (7%) p = 0.625 100 (88%) 38 (33%) 0.791
Negative 54 (90%) 50 (93%) 10 (9%) 4 (4%)
aincludes N1, N2a, N2b, N2c and N3.
bSOD = Stage of Disease.
cIn the further analyses, these three are merged.
dIRF = Intergrading risk factors.
elight drinker = less than once a week; heavy drinker = more than once a week or daily.
fN = 114 in the p16 analysis.
*p < 0.05 was regarded as statistically significant, and highlighted in boldface when present.
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and an consensus was achieved.
Statistics and analyses
The statistical analyses were performed using IBM SPSS
statistics for Windows (IBM Corporation Armonk, New
York), version 21. Associations between different categor-
ical variables were assessed with Pearson’s chi-square test
and Pearson correlation. Comparing of means was done
using the ONE-Way ANOVA-test. Univariate analyses of
time from diagnosis to death were performed using the
Kaplan-Meier method, and differences between categories
were estimated by the log-rank test, with the date of
diagnosis as starting point. The influence of covariates
on patient survival was analysed by multivariate analysis
(proportional hazard method). The last day of follow-up
was 01.01.2012. All results were considered significant if
p ≤ 0.05.
To control for variation due to age the patients were
divided into five groups (≤50 years, 51–60 years, 61–70
years, 71–80 years and ≥81 years). We also constructed
a variable called “Integrading risk factors” (IRF) that
combine the factors smoking and alcohol, and a factor
called “Stage of disease” (SOD) that combined the T, N
and M-stage based on the American Joint Comitee on
Cancer (AJCC) staging system [34].
Results
Gender and age
The cohort consisted of 52% men and 48% women, giving
a male/female ratio of 1.1. All clinicopathological variables
defined by gender and survival analyses are summarized
in Table 1. The mean age at diagnosis was 66.3 years, 64.9
for men (range 29–93) and 67.7 (range 27–90) for women.The mean overall survival from diagnosis was 56.7 months
for men and 88.3 months for women, a difference that
was statistically significant (p = 0.021).
Forty-seven (35%) of the 133 patients (35%) died of
the disease within 5 years from diagnosis, 41% of the men
and 30% of the women. Although the women in general
lived longer than the men, the difference in 5 years disease
specific survival was not statistically significant (p = 0.189).
There was a tendency that women were diagnosed with
smaller tumours (lower T-stage) than men (p = 0.078).
Nine patients (7%) were younger than 45 years at the
time of diagnosis, which completely coincide with what has
been reported globally [6]. Three of these young patients
died of the disease.
The risk of dying of the disease within 5 years was the
same in all age-groups, see Table 1. There was no signifi-
cant association between age and primary site, grade of
tumour differentiation, p16-status, tumour size (T) nor the
presence of regional metastasis (N). However, the youngest
and eldest patients smoked less tobacco (p = 0.008), and
consumed significantly less alcohol (p = 0.002) compared to
the middle-aged, see Figure 1a and b.
Anatomic site and classification
The majority of the tumours arose in the mobile tongue
(46%), floor of mouth (23%) and alveolar ridge (18%)
(Table 1). There was a significant correlation between
gender and primary site (p = 0.015), men accounting for
70% of the tumours in the floor of mouth, while tumours
of the alveolar rim being most frequently diagnosed in
women (63%) (Table 2).
Most of the tumours were well (41%) or moderately
differentiated (46%) and 4% of the tumours showed a
verrucous growth pattern. There was a higher occurrence
Figure 1 A graphical illustration of the relation between smoking
(a) and alcohol consumption (b) in the different age-groups. The
columns are split by gender.
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tumours, but this was not statistical significant.Smoking and alcohol
Smoking and drinking habits of the 133 patients are
listed in Table 1. As this was a retrospective study, it was
not possible to specify the amount of tobacco and alcohol
use in pack-years or units due to unstandardized reporting
in the patients’ files. As expected, there was a strong cor-
relation between smoking and drinking (p = 0.01), and a
significant predominance of men among both smokers
and drinkers (p < 0.001). Compared to non-smokers
and abstinent patients, smokers and drinkers presented
with significantly larger tumours (p = 0.002 for smoking,
p = 0.017 for drinking) and a higher frequency of regional
node spread of the disease (p < 0.001 for smoking, p = 0.002for drinking). There was a highly significant correlation
between smoking and drinking and SOD (p < 0.001).
For the whole cohort, there was also a highly significant
correlation between both smoking and drinking and pri-
mary site (p < 0.001 for both). 36% of the patients with
tumours in the mobile tongue were smokers compared to
73% of the patients with tumours arising in floor of
mouth. Only 8% of the patients with tongue cancers were
recorded to be drinking more than once a week or daily
compared to 40% of patients with cancers in the floor of
the mouth. When stratified on gender, the correlation be-
tween smoking and primary site was statistically signifi-
cant for both men and women (p = 0.047 and p = 0.007
respectively), but only women showed a statistically sig-
nificant correlation between drinking habits and primary
site (p = 0.017 vs. 0.061 for men) (Table 2).
HPV-related tumours
p16 expression is often used as an indirect indicator of
HPV infection in the tumour cells in clinical practice
[32]. Of the 114 patients that we assessed for p16 expres-
sion in their primary tumour, 9% were p16 positive
(Table 1). For 16 of the patients, tissue from lymph node
metastasis were also stained, which showed that p16 ex-
pression in the primary tumours and the metastatic foci
correlated completely (2 positive/14 negative). There was
no correlation between p16-status and 5 years survival
rate, site of tumor or any of the other clinicopathological
variables.
Mortality
As expected, we found that tumour size, presence of re-
gional lymph node metastasis, as well as the compounded
factor SOD, correlated with DSD (p < 0.001, p = 0.001 and
p < 0.001, respectively, Figure 2). Furthermore, high alco-
hol consumption increased the 5-years risk of dying of the
disease, both for the whole cohort (p = 0.002) and when
stratified on men and women (p = 0.039 and p = 0.001).
None of the other variables showed any statistically sig-
nificant association with 5-year DSD.
In a multivariate Cox regression analyses, including
primary site, SOD, smoking and drinking, only SOD was
significant for the whole cohort. Though, when evalu-
ating genders separately, also drinking habits and the
Integrading risk factors (IRF) variable were independ-
ent prognostic factors in women (p = 0.01 and p = 0.02,
respectively).
Discussion
We have demonstrated that our North Norwegian cohort
of patients with oral cancer is comparable with other
groups investigated in international studies in most
aspects.
Table 2 Smoking and alcohol consume in relation to primary site
Men Mobile tounge Floor of mouth Alveolar rim Othera p*
Total 34 (49%) 21 (30%) 9 (13%) 5 (7%)
Smoking
Never 7 (21%) 1 (5%) 0 0 p = 0.047
Previous 8 (24%) 2 (10%) 2 (22%) 2 (40%)
Smoker 17 (50%) 17 (81%) 6 (67%) 1 (20%)
Unknown 2 (6%) 1 (5%) 1 (11%) 2 (40%)
Drinking
Never 4 (12%) 1 (5%) 0 0 p = 0.061
< once a week 18 (53%) 4 (19%) 4 (44%) 1 (20%)
> once a week 2 (6%) 6 (29%) 1 (11%) 0
Daily 2 (6%) 5 (24%) 0 1 (20%)
Unknown 8 (24%) 5 (24%) 4 (44%) 3 (60%)
Women Mobile tounge Floor of mouth Alveolar rim Othera p*
Total 27 (42%) 9 (14%) 15 (23%) 13 (20%)
Smoking
Never 17 (63%) 1 (11%) 6 (40%) 3 (23%) p = 0.007
Previous 3 (11%) 1 (11%) 1 (7%) 1 (8%)
Smoker 5 (19%) 5 (56%) 1 (7%) 7 (54%)
Unknown 2 (7%) 2 (22%) 7 (47%) 2 (15%)
Drinking
Never 14 (52%) 0 6 (40%) 3 (23%) p = 0.017
< once a week 9 (33%) 5 (56%) 2 (13%) 4 (31%)
> once a week 0 1 (11%) 0 0
Daily 1 (4%) 0 2 (13%) 2 (15%)
Unknown 3 (11%) 3 (33%) 4 (27%) 4 (31%)
*p < 0.05 was regarded as statistically significant, and highlighted in boldface when present.
aincludes buccal mucosa, palate and unspecified site in the oral cavity.
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presented with well or moderately differentiated tumours,
most frequently located in the mobile tongue, floor of
mouth and alveolar rim [1,35]. As reported in a North
American study by Koch et al., we found that the smokers
and drinkers were diagnosed between the fifth and sev-
enth decades of life [12]. There were less smokers and
drinkers among the youngest and oldest individuals, who
frequently presented tumours in the mobile tongue.
This is also consistent with previous published data
[12]. Tumours arising in the floor of mouth were by far
more frequent in male patients with a high consume of
both tobacco and alcohol (Table 2). This has also been
reported by others, and has been explained by the accu-
mulation of carcinogens in the mucus in the floor of the
mouth [1,12].
Our results indicate that alcohol is a more potent risk
factor for development of OSCC than smoking. La
Vecchia et al. [7] claims that alcohol has a major relevance
in defining the individual risk of oral cancer. They describea rising trend in oral cancer up to the mid 1990 in Europe,
reflecting the expanding epidemic of all tobacco-related
neoplasms in those countries. Though, over the last de-
cades there has been a fall in lung cancer, but a persistent
unfavourable trend in oral cancer in males from the UK,
essentially attributable to changes in alcohol habits. Fur-
thermore, we found that the correlation between drinking
and DSD was stronger in women than in men. In the
multivariate analysis, increased alcohol consumption was
a significant risk factor for disease specific death in women,
but not in men or the whole cohort. Other studies have
also claimed that women are more vulnerable to the harm-
ful effects of alcohol than men [36].
In our study we found a male/female ratio of 1.1, which
is somewhat lower than reports from other countries in
Northern Europe, like Denmark and the UK, where the
ratio vary between 1.3 to 2.0 [4,6,37]. There is however a
global trend of decreasing differences between genders
[3,8]. The Cancer registry of Norway, which publish data
in cancer incidence, mortality, survival and prevalence in
Figure 2 Kaplan Meier curve illustrating the disease specific
survival in relation to stage of disease (SOD).
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women for cancer categorized as mobile tongue and
mouth (3.0 and 1.4/100 000) (ICD-O, C02-C06) [33].
However, for the three northernmost counties in Norway,
representing our impact area, the ratio in the national
statistics was 1.3:1 (2.6 and 2.0/100 000) which is in ac-
cordance with the distribution found in our study. Thus
the North Norwegian population does indeed seem to
have a slightly lower ratio between men and women
than reported elsewhere.
According to available data for alcohol consumption in
Norway in 1999, men consumed 4.82 litres of pure alcohol
per year (35% classified as hard liquor), and women 1.94
(20% hard liquor) [38]. The numbers in the three north-
ernmost counties did not differ much from the rest of
Norway [39]. There are no reliable studies reporting
amount and type of alcohol consumed in men and women
in the different regions of Norway, although many
speculate that moonshine (illegally distillate spirits) is
consumed to a somewhat larger degree by both gen-
ders in the northern part of Norway. Several studies
have shown that hard liquor have a larger impact on
OSCC-development than wine and beer [13,40,41].
In our material, which is not adjusted for age, there
was a tendency for an increased proportion of women in
the higher age-groups. Statistics of Norway reveal that in
1995 women in Norway had an overall 6 year longer life
expectancy then men [42]. This longer life-expectancy
for women, and the lack of adjustment for this in our
material, might explain that the male/female ratio was
somewhat low, despite the fact that men drank significantly
more than women.The 5-year risk for DSD was 35% for the whole cohort,
41% for the men and 30% for the women respectively,
which is somewhat lower than often reported [43,44].
The difference between men and women was not statisti-
cally significant. The majority of the patients in our study
were diagnosed with an early stage disease, presenting
with small (T1 (30%) or T2 (33%)) primary tumours and
82 out of 133 patients (62%) without detectable lymph
node metastasis. This may in part be due to a well-
functioning health-care system providing easy access and
good treatment prospects. Women were in general diag-
nosed with smaller tumours than men, which suggest that
they are diagnosed at an earlier stage of tumour develop-
ment. The longer survival could partly be a result of earl-
ier diagnosis, and not the fact that women survive longer
than men (lead time bias).
In 2001, Mork et al. [28], reported the proportion of
HPV-related tumours in the oral cavity of Scandinavian
head and neck-cancer patients to be 6.8%. This corre-
lates well with our numbers where 8.7% of the tumours
were p16 positive. However, in the study by Mork, all of
the HPV-positive tumours arose in the mobile tongue,
giving a frequency of 14% at this specific site. In our ma-
terial there was a small, but not statistically significant
difference in p16-positivity in tumours of the mobile
tongue (11%) compared to the rest of the oral cavity
(7%). In most studies, HPV-positivity has been found to
correlate with a favourable prognosis for carcinomas in
the oropharynx, but in line with our results, such a cor-
relation are seldom reported for carcinomas in the oral
cavity or other sub sites in the head and neck region
[29,45]. There has also been reported a higher degree of
HPV-negative carcinomas among smokers [12], but there
was no such tendency in our material.
Conclusion
Our study confirms that the North Norwegian OSCC
patient is representative of the general OSCC patient in
Europe, both regarding primary site, the stage of the dis-
ease and associations with risk factors such as smoking
and drinking. This is important when considering the
applicability of results from biomarker studies performed
on this material to other cohorts. Likewise, results from
other studies can be applicable for the population of
Northern Norway.
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